Health

Unyte Health Launches Sonocea Enhanced Rest and Restore Protocol: Revolutionary Approach for Nervous System Regulation

DENVER, June 19, 2025 (GLOBE NEWSWIRE) -- Unyte Health, a leader in nervous system health technology and sound-based interventions, is…

10 months ago

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting – Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC Pink: VINC) today announced that the Special…

10 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

June 18, 2025 16:05 ET  | Source: Annexon Biosciences Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and…

10 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

June 16, 2025 19:20 ET  | Source: PolyPid Ltd. The Company Anticipates that with this Additional Funding, PolyPid’s Runway would…

10 months ago

Dr. Elad Yossefi and Dr. Tal Yossefi Introduce Tech-Enhanced Dental Services in Norwalk

Norwalk, CT / USA, June 16, 2025 (GLOBE NEWSWIRE) -- Norwalk, CT — Advanced Dental Center in Norwalk, Connecticut, led…

10 months ago

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

June 16, 2025 18:40 ET  | Source: Enzo Biochem, Inc. FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem,…

10 months ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

10 months ago

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…

10 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

10 months ago